First fiscal quarter revenue and core operating profit both declined 0.5% year-on-year. Reported figures benefited from currency tailwinds of 10% and 11%, respectively. Management reiterated full-year guidance of 3% reported revenue growth and about 25% core operating profit margin.
Takeda now has three late-stage assets with blockbuster potential: zasocitinib, rusfertide, and oveporexton.
It will be difficult to improve the core operating profit margin in the near term because of elevated costs from new product launches and research and development.
|
Metric
|
4502
|
4519
|
JNJ
|
|---|---|---|---|
Price/Earnings (Normalized) | 46.39 | 23.53 | 24.16 |
Price/Book Value | 1.15 | 5.57 | 7.44 |
Price/Sales | 1.88 | 8.41 | 6.54 |
Price/Cash Flow | 10.54 | 21.23 | 22.39 |
|
Metric
|
4502
|
4519
|
JNJ
|
|---|---|---|---|
Quick Ratio | 0.54 | 3.43 | 0.73 |
Current Ratio | 1.14 | 4.35 | 1.09 |
Interest Coverage | 0.07 | 9,780.06 | 25.00 |
|
Metric
|
4502
|
4519
|
JNJ
|
|---|---|---|---|
Return on Assets (Normalized) | 5.53% | 19.65% | 13.42% |
Return on Equity (Normalized) | 11.34% | 23.42% | 32.69% |
Return on Invested Capital (Normalized) | 7.74% | 23.42% | 20.33% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|!<ynrBl^ | LOCK|?!sZ | $69B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| LOCK|bH<#PS%! | LOCK|<b^p | $43B | |||
| Haleon PLC ADR
HLN
| LOCK|g#mr>> | LOCK|s&V | $42B | |||
| Zoetis Inc Class A
ZTS
| LOCK|D@d&PT? | LOCK|^&F | $30B | |||
| Viatris Inc
VTRS
| LOCK|Y?kcw@g | LOCK|sh$ | $19B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|k>$ | LOCK|#$c | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|$nz#%P< | LOCK|$rY | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|JV^t#fd | LOCK|$lf | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|<#^tJ#W | LOCK|<<V! | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|?$#GGk@ | LOCK|yNQ | $2B |
United States